CTC
TXMD icon

Central Trust Company’s TherapeuticsMD TXMD Stock Holding History

Central Trust Company’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-36
Closed -$2K – 1156
2020
Q1 		$2K Hold
36
– – ﹤0.01% 1084
2019
Q4 		$4K Hold
36
– – ﹤0.01% 1087
2019
Q3 		$7K Buy
+36
New +$5.07K ﹤0.01% 974

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Central Trust Company's TXMD Position: Q2 2020 in Review

Central Trust Company sold out of TherapeuticsMD (TXMD) in Q2 2020, closing a stake of 36 shares — an estimated $2K sold.

Central Trust Company first reported a position in TXMD in Q3 2019 and held it in 3 quarters. The position peaked at $7K in Q3 2019. 149 funds tracked by Wall St. Rank hold TXMD as of Q2 2020.

  • Central Trust Company reported no remaining TherapeuticsMD position as of Q2 2020 after selling out during the quarter.
  • Central Trust Company sold 36 TherapeuticsMD shares in Q2 2020, an estimated $2K.
  • Central Trust Company first reported a position in TherapeuticsMD in Q3 2019 and held it in 3 quarters.
  • Central Trust Company's TherapeuticsMD position peaked at $7K in Q3 2019.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2020.

Based on Central Trust Company's 13F filing for Q2 2020, filed 14 Jul 2020.